title: Pembrolizumab in recurrent advanced cervical squamous carcinoma.
abstract: No definitive cure is known for recurrent, persistent or metastatic cervical carcinoma. Chemotherapy remains the standard of care, although available options are scarce and do not provide satisfactory results. Immune checkpoint inhibitors have shown a strong and prolonged response in several types of cancer, although only in a subset of patients. Defining the profile of the patients likely to benefit from such treatment is a subject of active research. Here, we present a case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatment options and showed a striking response to the immune checkpoint inhibitor pembrolizumab.
authors.affiliation: Oncology Department, Clínica Diagonal, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Martínez
authors.affiliation: Oncology Department, Clínica Diagonal, Esplugues de Llobregat, Barcelona, Spain.
authors.forename: Josep María
authors.initials: JM
authors.lastname: Del Campo
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D002584:Cervix Uteri / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012074:Remission Induction; D047368:Tumor Burden / Q000187:drug effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab
keywords: cervical squamous carcinoma; immuno-oncology; pembrolizumab PD-1 inhibitors